Pharma is entering a period of structural change in how innovation is converted into patient impact.
Commercial models that were highly effective for decades built around scale, promotion, and late-stage demand creation are now under pressure from forces outside any single organization’s control.
Standardized testing across health systems, increased payer scrutiny, accelerating patent cliffs, and rising expectations for precision and speed are reshaping how value is created and captured. In this environment, success increasingly depends on how Diagnostics, Data, and Digital execution work together not as individual capabilities, but as a unified commercial operating model.
Drawing on insights from the D-Cubed Pharma report, this webinar explores how leading biopharma companies are adapting their commercial approach to these realities. We will examine where traditional models begin to show friction, where value can leak between approval and treatment, and how more integrated, diagnostics-led activation models are helping organizations reach eligible patients faster and more efficiently.
Through real-world examples including diagnostic-triggered engagement, real-time lab intelligence, and precision digital activation speakers will share what is working in practice, what organizations have learned along the way, and how early adopters are scaling these approaches across portfolios.
Join us to understand what is changing, why it matters now, and how leading organizations are building scalable, future-ready commercial models designed for 2026 and beyond.